# PPAR-COMBO With Sulfonylurea

> **NCT00162175** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 534 (—)

## Conditions studied

- Metabolics Diabetes Nos

## Interventions

- **DRUG:** Muraglitazar

## Key facts

- **NCT ID:** NCT00162175
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 534 (—)
- **Last updated:** 2010-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162175, "PPAR-COMBO With Sulfonylurea". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00162175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*